BMS signs fibrosis deal with Danish biotech company
A Danish biotech company is now going to develop biomarkers for US-based drug group Bristol-Myers Squibb to potentially aid in diagnosing and monitoring fibrotic diseases, including fatty liver disease NASH.
BY MARTIN HAVTORN PETERSEN
Log in to read our articles
Welcome to MedWatch. A part of our content is exclusive and reserved for our users.